Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

This study will evaluate the safety and effectiveness of a combination of study drugs including zimberelimab, etrumadenant, and quemliclustat in combination with metastasis-directed irradiation in men with hormone sensitive oligometastatic prostate cancer. The study aims to test the hypothesis that targeted inhibition of the adenosine signaling axis (quemliclustat (CD73 antagonist) + etrumadenant (A2AR/A2BR antagonist)) and immune checkpoint inhibition (zimberelimab, α-PD-1) in combination with metastasis-directed stereotactic body radiation therapy (SBRT) will improve local control, progress

Trial Details

NCT ID
NCT05915442
Phase
PHASE2
Sponsor
Catherine Spina
Status
RECRUITING
Cancer Type
Hormone-Sensitive Prostate Cancer
Interventions
  • Quemliclustat
  • Etrumadenant
  • Zimberelimab
  • Stereotactic Body Radiation Therapy
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Patient must have histologically confirmed adenocarcinoma of the prostate.
  • Patient's primary prostate cancer tumor treated with surgery and/or radiation (+/- ADT).
  • Patients must have one to three asymptomatic metastatic tumors of the bone or soft tissue that developed in the preceding 6 months that are \< 5cm …
  • Prostate-specific antigen (PSA) \> 0.5 ng/mL but \< 50ng/ml

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hormone-Sensitive Prostate Cancer Trials on Trialify →